HIV
Helping to End the HIV Epidemic Worldwide

Some of the content on this page is not intended for users outside the U.S.

Our extensive early research and development program is the foundation of our efforts to help end the HIV epidemic. Our scientists are dedicated to discovering the next generation of medical breakthroughs, including alternate dosing schedules and routes of administration, to improve the lives of people impacted.

We introduced the first once-daily oral medication for pre-exposure prophylaxis (PrEP) to help prevent HIV transmission between sexual partners when taken as prescribed. This development gave people around the world an entirely new kind of powerful HIV prevention option.

Now, we're developing and expanding access to existing and additional PrEP options. This is an essential step forward in HIV preventative care, and one that could increase the impact our PrEP medicines have in bringing down new infections around the world.

To continue making this kind of progress in HIV prevention, we’re proud to partner with members of communities affected by HIV to help close gaps in prevention research for disproportionately affected and underrepresented populations. Our goal is to work with these partners to eliminate barriers to care and make HIV prevention more accessible to the individuals and communities who need or want it.

Gilead researchers have developed therapies that are leading the global response to HIV. And, thanks to incredible progress across the HIV treatment community, effective treatments that suppress viral replication are now broadly available. This includes advancements such as modern once-daily single tablet regimens and long-acting injectable options that enable individuals who are taking and staying on treatment to lead longer and healthier lives.

These innovations, which are aimed to meet the changing needs and preferences of diverse communities impacted by the virus, are helping improve antiretroviral treatment effectiveness and engagement in care.

Nevertheless, HIV persists as a serious public health challenge. We recognize that ending the epidemic requires close partnership with the entire HIV community. By exploring how our medicines work in communities shouldering a disproportionate burden of the epidemic and advancing innovative treatment strategies that could drive more equitable and comprehensive access to HIV care, our goal is to bring forward effective therapy options to everyone who needs them.

HIV treatment and prevention is entering a new era where more therapeutic options are emerging for people living with HIV and those who need or want PrEP.

Once-daily single tablet regimens have helped bring radical change in the outlook for people living with HIV. Yet significant gaps in care still remain. Some people face challenges with adherence due to limited treatment options or regimen complexity. In certain areas around the globe, taking daily pills may also be a stigmatizing burden.

Our goal is to discover and develop innovative HIV medicines. We believe the next wave of innovation in HIV includes long-acting options that are aiming to help address the differentiated needs and preferences of the diverse range of individuals and communities affected by the epidemic.

Curing HIV remains the ultimate aspiration of Gilead’s research and development efforts.

While HIV treatment has advanced dramatically over the past three decades, antiretroviral therapy (ART) remains the standard of care. Since the start of the epidemic, we’ve been pursuing potential pathways to achieve a cure for HIV that’s efficacious, scalable and accessible, and that results in permanent freedom from HIV for people who have it.

Our efforts toward a cure are beginning to show incremental but impactful progress. We’re working with partners on a “clear and control” approach aimed at clearing or reducing the HIV reservoir in a person’s cells, and then using the person’s immune system to control any remaining HIV. This study’s regimen may deliver prolonged periods for people with HIV to safely live without ART. More importantly for long-term progress in the cure field, the study will also help inform what is needed to drive progress toward the ultimate aspiration of a cure.

We know it will take more than medicine alone to end the HIV epidemic for everyone, everywhere.

The social, cultural and structural barriers that exist in our world need to be addressed as part of global HIV elimination efforts. We have a long history of working alongside the HIV community to achieve more equitable access to HIV care and services. Our cutting-edge research programs focus on the needs of people who are disproportionately impacted by HIV and traditionally underrepresented in studies. And through unique partnerships and access programs, we're working to improve HIV treatment and prevention education, support systems and policies that help facilitate broader uptake of medications and eliminate stigma and other barriers to care.

Today we are one of the largest private funders of non-profit HIV programs in the world. However, our work isn’t done until we have positively impacted the lives of all the people and communities impacted by HIV.

Our Impact to Date

75%

Of people worldwide living with HIV receive a Gilead-innovated treatment regimen

16.5

Million people in low- and middle-income countries access a Gilead-innovated HIV therapy

2,000+

Organizations supported to address stigma, health and racial disparities in HIV

Our-Hiv-Corporate-Giving-Programs-Mobile

COMMUNITY COMMITMENTS

We understand that it takes both science and social change to help end the HIV epidemic worldwide. It’s only by supporting and working with advocates and organizations across the country that we can reach this collective goal.

Learn about Gilead's Strategic Initiatives

COMPASS

The Gilead COMPASS Initiative is a 10-year, $100+ million partnership with community-based organizations working to combat the HIV epidemic in the Southern U.S.

RADIAN

RADIAN aims to address new HIV infections and deaths from AIDS-related illnesses in the Eastern Europe and Central Asia region.

TRANScend

The TRANScend Community Impact Fund supports Trans-led organizations working to improve the safety, health and wellness of the Transgender community.

HIV Age Positively

HIV Age Positively supports programs focused on improving the quality of life and health for those who are aging with HIV.

Zeroing In: Ending the HIV Epidemic

The Zeroing In grant program supports organizations worldwide that are working to improve the overall health and wellness of communities most impacted by the HIV epidemic.

Setting the P.A.C.E. – Prevention, Arts and Advocacy, Community

The Setting the P.A.C.E. initiative supports HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls.

Our Approach to Helping End the Epidemic

Closing the HIV Diagnosis Gap in Germany
COMPASS & Gilead HIV: Wake Forest University is creating a culture of empathy within faith communities in the Southern U.S.
Barbershop Talk & Gilead HIV: In this community-led approach to HIV education, a sexual health clinic based in Cairns, Australia, partners with barbers to bring the conversation about HIV to locals.
Arianna’s Center & Gilead HIV: Arianna Lint founded this organization to empower the transgender community in South Florida and Puerto Rico.

Stories@Gilead

Follow our journey to create a healthier world for all people

Scientific Innovation
Designing Inclusive Clinical Trials in an Effort to Upend the HIV Epidemic
November 07, 2024
People and Culture
Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer
October 14, 2024
Access and Health Equity
New Report Shows Every Country in the World Must Do More to End the HIV Epidemic
September 30, 2024
Scientific Innovation
Working to Build Next-Generation Cancer Therapies
September 10, 2024
Access and Health Equity
Championing HIV Services for LGBTQ+ Youth
September 05, 2024

View Stories@Gilead

HIV Helping to End the HIV Epidemic Worldwide